Bernstein analyst Eve Burstein maintained a 'Hold' rating on Illumina on Thursday, setting a target price of $215.00. The company's stock closed at $270.00 on Thursday.

According to the data from TipRanks, Burstein is a five-star analyst with an average return rate of 27.5% and a success rate of 78.00%. Burstein covers the healthcare sector, with a focus on stocks such as Agilent, Thermo Fisher, and Waters.

In addition to Bernstein, Illumina also received a "Hold" rating in the report published on September 11 by analyst Kyle Mikson CFA from Canaccord Genuity. However, Stifel N, which issued the token laus, maintained a "Buy" rating for Illumina ( NASDAQ : ILMN ) on September 15.

According to the latest financial report for the quarter as of June 28th, as indicated by Illumina, the company's revenue for that quarter was 1.16 billion US dollars, with a net profit of 207 million US dollars. In contrast, during the same period last year, the company's revenue was 1.06 billion US dollars, and the net profit was 235 million US dollars.

Based on the recent trading activities of 69 insiders from the company, their sentiment towards the stock is generally negative. This indicates that in the past quarter, there has been an increase in the number of ILMN insiders selling company shares compared to earlier this year. Earlier this month, ILMN director Keith Meister sold 263,560 shares, cashing in a total of $57,199,200.67.

For more information regarding ILMN, please refer to the relevant reports.